ImmunityBio 過去の業績
過去 基準チェック /06
ImmunityBioの収益は年間平均-10.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間37.7% 89.8%割合で 増加しています。
主要情報
-10.42%
収益成長率
8.12%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | 89.84% |
| 株主資本利益率 | n/a |
| ネット・マージン | -606.15% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブ更新 • Jul 24
IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside
Analysts have reset their price target on ImmunityBio from $23 to $15. This reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.Seeking Alpha • Jul 16
ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
Summary ImmunityBio (IBRX) remains rated Hold as its $8bn+ valuation relies on future clinical and regulatory milestones, not current fundamentals. Anktiva's clinical data in NMIBC and NSCLC is encouraging, but competition is intense and label expansion is critical for long-term upside. Q1 2026 revenues reached $44.2m, but heavy operating losses and cash burn highlight the need for significant revenue ramp or new funding. Key risks include 'key man' dependence on Dr. Soon Shiong, lack of 2026 guidance, and the need for US approvals beyond NMIBC. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 10
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.
ナラティブ更新 • Jun 26
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.分析記事 • May 11
Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...新しいナラティブ • Apr 01
Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Mar 18
Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Mar 04
Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?分析記事 • Aug 07
Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
NasdaqGS:IBRX 1 Year Share Price vs Fair Value Explore ImmunityBio's Fair Values from the Community and select yours A...Seeking Alpha • Apr 29
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
Summary ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but recent product sales and supportive financing extend the cash runway, providing a potential growth opportunity. Strengths include data supporting new approvals and expanding Anktiva's market, though risks involve unclear lung cancer market size and significant liabilities. Upgrading IBRX stock to “Buy” due to likely 2025 catalysts: accelerating Anktiva sales, potential lung cancer approval, and expanding bladder cancer market. Read the full article on Seeking Alpha収支内訳
収支内訳
ImmunityBio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 141 | -855 | 163 | 238 |
| 31 Dec 25 | 113 | -351 | 150 | 219 |
| 30 Sep 25 | 83 | -349 | 158 | 185 |
| 30 Jun 25 | 57 | -367 | 157 | 185 |
| 31 Mar 25 | 31 | -409 | 159 | 186 |
| 31 Dec 24 | 15 | -414 | 169 | 190 |
| 30 Sep 24 | 7 | -588 | 165 | 202 |
| 30 Jun 24 | 1 | -598 | 161 | 199 |
| 31 Mar 24 | 0 | -601 | 144 | 201 |
| 31 Dec 23 | 1 | -583 | 130 | 232 |
| 30 Sep 23 | 1 | -458 | 129 | 232 |
| 30 Jun 23 | 1 | -473 | 117 | 256 |
| 31 Mar 23 | 1 | -430 | 101 | 266 |
| 31 Dec 22 | 0 | -417 | 109 | 242 |
| 30 Sep 22 | 1 | -400 | 93 | 241 |
| 30 Jun 22 | 1 | -376 | 103 | 218 |
| 31 Mar 22 | 1 | -370 | 119 | 209 |
| 31 Dec 21 | 1 | -347 | 127 | 192 |
| 30 Sep 21 | 0 | -323 | 124 | 186 |
| 30 Jun 21 | 0 | -301 | 112 | 174 |
| 31 Mar 21 | 1 | -264 | 97 | 154 |
| 31 Dec 20 | 1 | -222 | 61 | 140 |
| 30 Sep 20 | 2 | -176 | 56 | 110 |
| 31 Dec 19 | 2 | -158 | 46 | 112 |
| 31 Dec 18 | 3 | -84 | 29 | 47 |
質の高い収益: IBRXは現在利益が出ていません。
利益率の向上: IBRXは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: IBRXは利益が出ておらず、過去 5 年間で損失は年間10.4%の割合で増加しています。
成長の加速: IBRXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: IBRXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 59.3% ) と比較することは困難です。
株主資本利益率
高いROE: IBRXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/26 23:49 |
| 終値 | 2026/07/24 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ImmunityBio, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |